0001557240-15-000219.txt : 20150401 0001557240-15-000219.hdr.sgml : 20150401 20150331190244 ACCESSION NUMBER: 0001557240-15-000219 CONFORMED SUBMISSION TYPE: NT 10-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20141231 FILED AS OF DATE: 20150401 DATE AS OF CHANGE: 20150331 EFFECTIVENESS DATE: 20150401 FILER: COMPANY DATA: COMPANY CONFORMED NAME: EASTGATE BIOTECH CORP CENTRAL INDEX KEY: 0001099574 STANDARD INDUSTRIAL CLASSIFICATION: INVESTORS, NEC [6799] IRS NUMBER: 870639378 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: NT 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-52886 FILM NUMBER: 15740930 BUSINESS ADDRESS: STREET 1: 2681 EAST PARLEYS WAY - SUITE 204 CITY: SALT LAKE CITY STATE: UT ZIP: 84109 BUSINESS PHONE: 8013223401 MAIL ADDRESS: STREET 1: 2681 EAST PARLEYS WAY - SUITE 204 CITY: SALT LAKE CITY STATE: UT ZIP: 84109 FORMER COMPANY: FORMER CONFORMED NAME: EASTGATE ACQUISITIONS CORP DATE OF NAME CHANGE: 19991123 NT 10-K 1 dec3112-etvbi_nt10k.htm NT 10-K
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 12b-25

Commission File Number: 000-54360


NOTIFICATION OF LATE FILING
 
T Form 10-K
 
Form 20-F
 
Form 11-K
 
Form 10-Q
Form 10-D
 
Form N-SAR
 
Form N-CSR
   
 
For Period Ended: December 31, 2014
 
Transition Report on Form 10-K
 
Transition Report on Form 10-Q
Transition Report on Form 20-F
 
Transition Report on Form N-SAR
Transition Report on Form 11-K
   
 
For the Transition Period Ended: _______________________________________

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: _______________________________________

PART I
REGISTRANT INFORMATION
Full name of registrant
 
Eastgate Biotech Corp.
Former name if applicable
   
Address of principal executive office
 
2203-65 Harbour Square
City, state and zip code
 
Toronto, Ontario, Canada M5J 2L4
 
PART II
RULE 12b-25 (b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25 (b), the following should be completed. (Check box if appropriate.)

 
T
(a)        The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
(b)        The subject annual report, semi-annual report, transition report on Form 10-K, 20-F, 11-K or Form N-SAR or Form N-CSR, or portion thereof will be filed on or before the 15th calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
(c)        The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
 

PART III
NARRATIVE

State below in reasonable detail the reasons why Form 10-K, 11-K, 20-F, 10-Q, N-SAR, N-CSR, or the transition report portion thereof, could not be filed within the prescribed time period.

The compilation, dissemination and review of the information required to be presented in the Form 10-K for the relevant fiscal year has imposed time constraints that have rendered timely filing of the Form 10-K impracticable without undue hardship and expense to the registrant.  The registrant undertakes the responsibility to file such annual report no later than 15 days after its original due date.

PART IV
OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification
 
Brian Lukian
 
(801) 322-3401
(Name)
(Area Code)
(Telephone Number)
    
(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed?  If the answer is no, identify report(s).

                                                        T  Yes      No

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

                                                          Yes    T  No

If so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.


Eastgate Biotech Corp.
(Name of Registrant as Specified in Charter)

Has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

Dated:  March 31, 2015
 
/s/ BRIAN LUKIAN
 
 By:
Brian Lukian
   
Title:  Chief Financial Officer